Antidiuretic Hormone Receptor Antagonists
"Antidiuretic Hormone Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS.
| Descriptor ID |
D065092
|
| MeSH Number(s) |
D27.505.519.174 D27.505.696.560.311
|
| Concept/Terms |
Antidiuretic Hormone Receptor Antagonists- Antidiuretic Hormone Receptor Antagonists
- Vasopressin Antagonists
- Antagonists, Vasopressin
- Vasopressin Receptor Antagonists
- Antagonists, Vasopressin Receptor
- Receptor Antagonists, Vasopressin
- Antidiuretic Hormone Antagonists
- Antagonists, Antidiuretic Hormone
- Hormone Antagonists, Antidiuretic
|
Below are MeSH descriptors whose meaning is more general than "Antidiuretic Hormone Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Antidiuretic Hormone Receptor Antagonists".
This graph shows the total number of publications written about "Antidiuretic Hormone Receptor Antagonists" by people in this website by year, and whether "Antidiuretic Hormone Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidiuretic Hormone Receptor Antagonists" by people in Profiles.
-
Hyponatremia in the cancer patient. Kidney Int. 2020 10; 98(4):870-882.
-
Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer. 2014 Mar 01; 120(5):744-51.
-
Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012; 17(6):756-65.
-
Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat Clin Pract Nephrol. 2007 Feb; 3(2):82-95.
-
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency. J Med Chem. 2006 Jul 13; 49(14):4159-70.
-
Impaired ability to increase water excretion in mice lacking the taurine transporter gene TAUT. Pflugers Arch. 2006 Feb; 451(5):668-77.
-
Enhanced reactivity to vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage. Eur J Pharmacol. 2005 Apr 18; 513(1-2):93-100.
-
Acute effects of vasopressin V2-receptor antagonist on kidney AQP2 expression and subcellular distribution. Am J Physiol. 1998 08; 275(2):F285-97.
-
Effect of intracerebroventricular administration of vasopressin on stress-induced hyperthermia in rats. Physiol Behav. 1996 Aug; 60(2):417-24.